# US 2023/0057155 A1 · Dry liposome formulations and related methods thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0057155 A1
- Document ID: US20230057155A1
- Status: Published application
- Kind: A1
- Application number: 17/819,268
- Filed: 2022-08-11
- Published: 2023-02-23
- Earliest claimed: 2021-08-11
- Assignees: Board of Regents, The University of Texas System
- Applicants: Board of Regents, the University of Texas System
- Inventors: Zhengrong CUI; Robert O. WILLIAMS, III; Khaled ABOULFOTOUH
- Web page: https://patentgrep.com/patent/US20230057155A1

## CPC

- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/1277: Preparation processes; Proliposomes
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Described herein are dry powder compositions of liposomes. Formulations containing a cryoprotectant can be converted to dry powders using, e.g., thin-film freeze-drying (TFFD) to obtain stabilized composition that show improved properties.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

A method for preparing a thin film liposomal composition comprising:
applying a liquid liposomal composition and a sugar or a sugar alcohol to a freezing surface; and
allowing said liquid liposomal composition to disperse and freeze on said freezing surface thereby forming a thin film.

### Claim 17 (depends on 16)

The method of claim 16, wherein thin film liposomal composition further comprises a drug or biologic agent.

### Claim 18 (depends on 16)

The method of claim 16, wherein said liquid liposomal composition comprises dioleoyl phosphatidylcholine and cholesterol.

### Claim 19 (depends on 16)

The method of claim 16, wherein said thin film has a particle size distribution upon reconstitution within about 10-50% or about 30% of the range of the liquid liposomal composition.

### Claim 20 (depends on 16)

The method of claim 16, wherein said sugar or sugar alcohol is present at about a lipid to sugar and/or sugar alcohol ratio of about 1:0.6 to 1:30 w/w, respectively or about 1:250 to 1:1000 w/w, respectively.

### Claim 21 (depends on 16)

The method of claim 16, wherein the sugar or sugar alcohol is mannitol, sucrose and/or trehalose.

### Claim 22 (depends on 16)

The method of claim 16, wherein said thin film comprises less than about 5% water.

### Claim 23 (depends on 16)

The method of claim 16, wherein said thin film further comprises an excipient.

### Claim 24 (depends on 23)

The method of claim 23, wherein said excipient is a salt, a buffer, a detergent, a polymer, an amino acid, a second sugar or a preservative.

### Claim 25 (depends on 24)

The method of claim 24, wherein said excipient is disodium edetate, sodium chloride, sodium citrate, sodium succinate, sodium hydroxide, sodium glucoheptonate, sodium acetyltryptophanate, sodium bicarbonate, sodium caprylate, sodium pertechnetate, sodium acetate, sodium dodecyl sulfate, ammonium citrate, calcium chloride, calcium, potassium chloride, potassium sodium tartarate, zinc oxide, zinc, stannous chloride, magnesium sulfate, magnesium stearate, titanium dioxide, DL-lactic/glycolic acids, asparagine, L-arginine, arginine hydrochloride, adenine, histidine, glycine, glutamine, glutathione, imidazole, protamine, protamine sulfate, phosphoric acid, Tri-n-butyl phosphate, ascorbic acid, cysteine hydrochloride, hydrochloric acid, hydrogen citrate, trisodium citrate, guanidine hydrochloride, mannitol, lactose, agarose, sorbitol, maltose, trehalose, surfactants, polysorbate 80, polysorbate 20, poloxamer 188, sorbitan monooleate, triton n101, m-cresol, benyl alcohol, ethanolamine, glycerin, phosphorylethanolamine, tromethamine, 2-phenyloxyethanol, chlorobutanol, dimethylsulfoxide, N-methyl-2-pyrrolidone, propyleneglycol, polyoxyl 35 castor oil, methyl hydroxybenzoate, tromethamine, corn oil-mono-di-triglycerides, poloxyl 40 hydrogenated castor oil, tocopherol, n-acetyltryptophan, octa-fluoropropane, castor oil, polyoxyethylated oleic glycerides, polyoxytethylated castor oil, phenol, glyclyglycine, thimerosal, parabens, gelatin, Formaldehyde, Dulbecco’—s modified eagles medium, hydrocortisone, neomycin, Von Willebrand factor, gluteraldehyde, benzethonium chloride, white petroleum, p-aminopheyl-p-anisate, monosodium glutamate, beta-propiolactone, acetate, citrate, glutamate, glycinate, histidine, Lactate, Maleate, phosphate, succinate, tartrate, tris, carbomer 1342 (copolymer of acrylic acid and a long chain alkyl methacrylate cross-linked with allyl ethers of pentaerythritol), glucose star polymer, silicone polymer, polydimethylsiloxane, polyethylene glycol, polyvinylpyrrolidone, carboxymethylcellulose, poly(glycolic acid), poly(lactic-co-glycolic acid), polylactic acid, dextran 40, or poloxamer.

### Claim 26 (depends on 23)

The method of claim 23, comprising from about 60% to about 95% w/w of said excipient.

### Claim 27 (depends on 16)

The method of claim 16, wherein said liquid liposomal composition is exposed to said freezing surface from about 50 milliseconds to about 5 seconds.

### Claim 28 (depends on 16)

The method of claim 16, wherein exposure comprises spraying or dripping droplets of said liquid liposomal composition.

### Claim 29 (depends on 28)

The method of claim 28, wherein the freezing surface temperature is about -180° C. to about 0° C., the diameters of the droplets are about 2-5 millimeters, and the droplets are dropped from a distance about 2 cm to 10 cm from the freezing surface.

### Claim 30 (depends on 28)

The method of claim 28, further comprising contacting the droplets with a freezing surface having a temperature differential of at least about 30° C. between the droplets and the surface.

### Claim 31 (depends on 30)

The method of claim 30, wherein the freezing rate of said droplets is between about 10 K/second and about 103 K/second.

### Claim 32 (depends on 31)

The method of claim 31, further comprising removing the solvent from the thin film to form a dry composition optionally by lyophilization.

### Claim 33

(canceled)

### Claim 34 (depends on 32)

The method of claim 32, further comprising solvating said dry liposomal composition, thereby forming a reconstituted liquid composition.

### Claim 35 (depends on 34)

The method of claim 34, wherein the liquid liposomal composition further comprises a drug or biologic agent, wherein the drug or biological agent is an antifungal, an antibacterial, a cancer chemotherapeutical agent, a protein (e.g., enzyme, monoclonal antibody), or nucleic acid.

### Claim 36

(canceled)

### Claim 37 (depends on 16)

The method of claim 16, wherein the thin film liposomal composition is formulated as an aerosol/for inhalation.

### Claim at position 24

38-49. (canceled)
